ATE462424T1 - Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose - Google Patents

Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose

Info

Publication number: ATE462424T1
Authority: AT; Austria
Prior art keywords: nitrosoglutathione; cystic fibrosis; nebulated; therapeutic use; directed
Prior art date: 2000-10-16

Application number

AT01979236T

Other languages

English (en)

Inventor

Benjamin Gaston

Jonathan Stamler

Original Assignee

Univ Duke

Univ Virginia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-16

Filing date

2001-10-15

Publication date

2010-04-15

2001-10-15 Application filed by Univ Duke, Univ Virginia filed Critical Univ Duke

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE462424T1 publication Critical patent/ATE462424T1/de

Links

201000003883 Cystic fibrosis Diseases 0.000 title abstract 2
108010001742 S-Nitrosoglutathione Proteins 0.000 title abstract 2
HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 title abstract 2
230000001225 therapeutic effect Effects 0.000 title 1
QQZWEECEMNQSTG-UHFFFAOYSA-N Ethyl nitrite Chemical compound CCON=O QQZWEECEMNQSTG-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT01979236T 2000-10-16 2001-10-15 Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose ATE462424T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24070800P	2000-10-16	2000-10-16
PCT/US2001/027768 WO2002032418A1 (en)	2000-10-16	2001-10-15	Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis

Publications (1)

Publication Number	Publication Date
ATE462424T1 true ATE462424T1 (de)	2010-04-15

Family

ID=22907617

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01979236T ATE462424T1 (de)	2000-10-16	2001-10-15	Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose

Country Status (8)

Country	Link
US (2)	US6723703B2 (de)
EP (1)	EP1333823B1 (de)
JP (1)	JP4194364B2 (de)
AT (1)	ATE462424T1 (de)
AU (2)	AU1122202A (de)
CA (1)	CA2425489C (de)
DE (1)	DE60141703D1 (de)
WO (1)	WO2002032418A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7045152B2 (en) *	1999-09-08	2006-05-16	Duke University	Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US6314956B1 (en)	1999-09-08	2001-11-13	Duke University	Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
AU2001232787A1 (en) *	2000-01-14	2001-07-24	University Of Virginia Patent Foundation	Airway alkalinization as therapy for airway diseases
DE60141703D1 (de) *	2000-10-16	2010-05-12	Univ Duke	Therapeutische anwendung von zerstäubtem s-nitrosoglutathion bei zystischer fibrose
EP1427323A4 (de) *	2001-08-20	2004-09-15	Univ Virginia	Verwendung von s-nitrosothiol-signalisierung zur behandlung von störungen der atmungskontrolle
GB0125222D0 (en) *	2001-10-19	2001-12-12	Barts & London Nhs Trust	Composition for the treatment of microbial infections
US6627602B2 (en) *	2001-11-13	2003-09-30	Duke University	Preventing desensitization of receptors
US20040110691A1 (en) *	2001-11-13	2004-06-10	Stamler Jonathan S.	Thiol reactive agents as a therapeutic modality
JP5564158B2 (ja) *	2003-07-09	2014-07-30	ザガバメントオブザユナイテッドステイツオブアメリカアズリプレゼンテッドバイザセクレタリーオブザデパートメントオブヘルスアンドヒューマンサービシーズ	亜硝酸塩によって特定の心臓血管状態を処置する方法
US8518457B2 (en) *	2004-05-11	2013-08-27	Pulmonox Technologies Corporation	Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
US7362274B1 (en) *	2004-07-09	2008-04-22	Huan-Cheng Lien	Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
WO2006062732A2 (en) *	2004-11-19	2006-06-15	Synta Pharmaceuticals Corp.	Compounds acting at the centrosome
WO2006125123A2 (en) *	2005-05-19	2006-11-23	University Of Cincinnati	Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
EP1888510A4 (de)	2005-05-27	2013-01-16	Univ North Carolina	Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
US20070243262A1 (en) *	2005-12-21	2007-10-18	Hurley Kevin P	Stable S-nitrosothiol formulations
HUE048024T2 (hu)	2006-08-10	2020-05-28	Roy C Levitt	Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
WO2008134026A1 (en) *	2007-04-25	2008-11-06	Stc.Unm	Analysis of p. aeruginosa infection in patients
EP2237788A4 (de) *	2007-12-27	2013-06-05	Aires Pharmaceuticals Inc	Aerosolisierte nitrit- und stickoxidspendende verbindungen und ihre verwendung
BR112012003804B1 (pt)	2009-08-21	2019-02-19	Novan, Inc.	Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
WO2011022652A1 (en)	2009-08-21	2011-02-24	Novan, Inc.	Topical gels
US8591876B2 (en)	2010-12-15	2013-11-26	Novan, Inc.	Methods of decreasing sebum production in the skin
ES2695173T3 (es)	2011-02-28	2019-01-02	Novan Inc	Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
WO2014070769A1 (en)	2012-10-29	2014-05-08	The University Of North Carolina At Chapel Hill	Methods and compositions for treating mucosal tissue disorders
US9913801B2 (en) *	2013-02-15	2018-03-13	Your Energy Systems, LLC	Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione
KR20230117644A (ko)	2016-11-17	2023-08-08	레노비온, 아이엔씨.	글루타티온 조성물에 의한 호흡기 질환 및 감염 치료
ES3008699T3 (en)	2017-11-17	2025-03-24	Renovion Inc	Stable ascorbic acid compositions and methods of using the same
AT523662B1 (de) *	2020-03-16	2023-07-15	Aurovir Pharma Gmbh	Gold-haltige Mittel zur Behandlung von Lungeninfektionen
IL313997A (en)	2022-01-04	2024-08-01	Renovion Inc	Aqueous solution including glutathione salt

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4900719A (en) *	1988-08-05	1990-02-13	The Ohio State University	Nitrosothiols as hypotensive agents
US5380758A (en) *	1991-03-29	1995-01-10	Brigham And Women's Hospital	S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5728705A (en) *	1993-10-04	1998-03-17	The Trustees Of Columbia University In The City Of New York	Method of inducing vasorelaxation to treat pulmonary hypertension
US5859058A (en) *	1994-07-14	1999-01-12	Glaxo Wellcome Inc.	Nitric oxide synthase inhibitors for inhibiting the production of airway mucas
US5824669A (en)	1996-03-22	1998-10-20	Nitromed, Inc.	Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6331543B1 (en) *	1996-11-01	2001-12-18	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) *	1996-11-01	1999-09-28	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6617355B1 (en)	1997-05-21	2003-09-09	The University Of Virginia Patent Foundation	Treating asthma by preventing and/or accomodating S-nitrosothiol breakdown
DE19919941A1 (de) *	1999-04-30	2000-11-02	Dimitrios Tsikas	S-Nitroso-N-Acyl-L-Cystein-Ester-Derivate als pharmakologische Wirkstoffe und diese Verbindungen enthaltende Arzneimittel
US7045152B2 (en)	1999-09-08	2006-05-16	Duke University	Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US6314956B1 (en) *	1999-09-08	2001-11-13	Duke University	Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
US20020002136A1 (en) *	2000-06-28	2002-01-03	Hebert Rolland F.	Salts of glutathione
DE60141703D1 (de) *	2000-10-16	2010-05-12	Univ Duke	Therapeutische anwendung von zerstäubtem s-nitrosoglutathion bei zystischer fibrose
US6359182B1 (en)	2000-10-26	2002-03-19	Duke University	C-nitroso compounds and use thereof
US6627602B2 (en) *	2001-11-13	2003-09-30	Duke University	Preventing desensitization of receptors

2001
- 2001-10-15 DE DE60141703T patent/DE60141703D1/de not_active Expired - Lifetime
- 2001-10-15 AU AU1122202A patent/AU1122202A/xx active Pending
- 2001-10-15 AU AU2002211222A patent/AU2002211222B2/en not_active Ceased
- 2001-10-15 US US10/380,763 patent/US6723703B2/en not_active Expired - Lifetime
- 2001-10-15 AT AT01979236T patent/ATE462424T1/de not_active IP Right Cessation
- 2001-10-15 CA CA2425489A patent/CA2425489C/en not_active Expired - Fee Related
- 2001-10-15 WO PCT/US2001/027768 patent/WO2002032418A1/en not_active Ceased
- 2001-10-15 JP JP2002535656A patent/JP4194364B2/ja not_active Expired - Fee Related
- 2001-10-15 EP EP01979236A patent/EP1333823B1/de not_active Expired - Lifetime
2004
- 2004-02-06 US US10/772,374 patent/US20050131064A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2425489C (en)	2011-05-17
US20050131064A1 (en)	2005-06-16
JP4194364B2 (ja)	2008-12-10
EP1333823A4 (de)	2006-03-01
JP2004511515A (ja)	2004-04-15
EP1333823B1 (de)	2010-03-31
CA2425489A1 (en)	2002-04-25
WO2002032418A1 (en)	2002-04-25
DE60141703D1 (de)	2010-05-12
EP1333823A1 (de)	2003-08-13
US20030212004A1 (en)	2003-11-13
AU2002211222B2 (en)	2006-02-09
US6723703B2 (en)	2004-04-20
AU1122202A (en)	2002-04-29

Legal Events

Date	Code	Title	Description
2010-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE462424T1 (de)	2010-04-15	Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose
CY1124931T1 (el)	2022-11-25	Αντιμετωπιση της φαινυλκετονουριας με bh4
EE200400020A (et)	2004-04-15	Asendatud oksasolidinoonid kombineeritud raviks
NO982172L (no)	1998-05-13	Anvendelse av epinastin for behandling av smerter
ATE508735T1 (de)	2011-05-15	Pulmonale verabreichung von aminoglykosiden
UY27175A1 (es)	2002-09-30	Nueva sal succinato de o-desmetil- venlafaxina
DE60124684D1 (de)	2007-01-04	Sulfonamido-substituierte verbrückte bicycloalkylderivative
DK1178958T3 (da)	2004-06-21	N-cyanomethylamider som proteaseinhibitorer
CY1107054T1 (el)	2012-10-24	Ενωσεις διτοσυλικου αλατος κιναζολινης
SE0100901D0 (sv)	2001-03-15	New composition
CY1108610T1 (el)	2014-04-09	Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
MXPA04001256A (es)	2004-05-27	Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
ES2179096T3 (es)	2003-01-16	Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.
CY1109229T1 (el)	2013-09-04	Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
DE60101265D1 (de)	2003-12-24	Behandlung von augenschmerzen
CY1108446T1 (el)	2014-04-09	Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας
SE0101932D0 (sv)	2001-05-31	Pharmaceutical combinations
CY1109001T1 (el)	2014-07-02	Οι καππα-οπιοιδεις αγωνιστες στη θεραπεια των παθησεων της κυστης
EA200501310A1 (ru)	2006-06-30	Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
DE60101559D1 (de)	2004-01-29	Benutzung von comt-inhibitoren als analgetika
DE60018422D1 (de)	2005-04-07	Typ v pde-hemmer zur behandlung von mukoviszidose
SE0004101D0 (sv)	2000-11-09	New use
EA200300639A1 (ru)	2003-12-25	Применение sarp-1 для лечения и/или предупреждения склеродермии
AP2049A (en)	2009-09-25	Medicament containing activated antithrombin III
TR200302134T4 (tr)	2004-01-21	2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.